Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Authors
Keywords
Gene fusion, Health-related quality of life, Larotrectinib, NTRK, Quality of life, Tropomyosin receptor kinase
Journal
CURRENT PROBLEMS IN CANCER
Volume -, Issue -, Pages 100734
Publisher
Elsevier BV
Online
2021-04-02
DOI
10.1016/j.currproblcancer.2021.100734
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
- (2020) A.P. Conley et al. ANNALS OF ONCOLOGY
- Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
- (2019) Fabrice Barlesi et al. Journal of Thoracic Oncology
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- (2019) Sebastian Michels et al. Journal of Thoracic Oncology
- Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire
- (2018) Marieke van Leeuwen et al. Health and Quality of Life Outcomes
- New Agents, Emerging Late Effects, and the Development of Precision Survivorship
- (2018) Eric J. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
- (2018) S. Nolte et al. EUROPEAN JOURNAL OF CANCER
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Current and Evolving Methods to Visualize Biological Data in Cancer Research
- (2016) Puey Ling Chia et al. JNCI-Journal of the National Cancer Institute
- Current and Evolving Methods to Visualize Biological Data in Cancer Research
- (2016) Puey Ling Chia et al. JNCI-Journal of the National Cancer Institute
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- (2013) Grace K. Dy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Early palliative care in cancer treatment: rationale, evidence and clinical implications
- (2013) Lynn Howie et al. Therapeutic Advances in Medical Oncology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
- (2010) R. Sridhara et al. JNCI-Journal of the National Cancer Institute
- The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
- (2010) A. E. McKee et al. ONCOLOGIST
- The PedsQL™ Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants
- (2010) James W. Varni et al. QUALITY OF LIFE RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now